- Home
- LH vs RPRX Comparison
LH vs RPRX Comparison
Compare LH & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LH | RPRX |
|---|---|---|
| Founded | 1971 | 1996 |
| Country | United States | United States |
| Employees | 70000 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.6B | 19.5B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LH | RPRX |
|---|---|---|
| Price | $273.44 | $48.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $311.33 | $47.75 |
| AVG Volume (30 Days) | 494.2K | ★ 2.8M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | 1.05% | ★ 1.96% |
| EPS Growth | ★ 18.33 | N/A |
| EPS | ★ 10.46 | 1.78 |
| Revenue | ★ $13,951,700,000.00 | $2,378,193,000.00 |
| Revenue This Year | $8.30 | $38.30 |
| Revenue Next Year | $4.79 | $4.80 |
| P/E Ratio | ★ $26.29 | $26.93 |
| Revenue Growth | ★ 7.25 | 5.06 |
| 52 Week Low | $209.38 | $30.96 |
| 52 Week High | $293.72 | $49.06 |
Technical Indicators
Market Signals| Indicator | LH | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 63.70 |
| Support Level | $272.32 | $35.32 |
| Resistance Level | $281.62 | N/A |
| Average True Range (ATR) | 5.95 | 1.00 |
| MACD | 1.23 | 0.08 |
| Stochastic Oscillator | 79.45 | 88.11 |
Price Performance
Historical ComparisonAbout LH Laboratory Corporation of America Holdings
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.